Ancestry, ethnicity, and race: explaining inequalities in cardiometabolic disease

被引:0
|
作者
V. Eastwood, Sophie [1 ]
Hemani, Gibran [2 ,3 ]
Watkins, Sarah H. [2 ,3 ]
Scally, Aylwyn [4 ]
Smith, George Davey [2 ,3 ]
Chaturvedi, Nishi [1 ]
机构
[1] UCL, Inst Cardiovasc Sci, MRC Unit Lifelong Hlth & Ageing, UCL Populat Sci & Expt Med,Fac Populat Hlth Sci, London, England
[2] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[3] Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit, Populat Hlth Sci, Bristol, England
[4] Univ Cambridge, Dept Genet, Downing St, Cambridge, England
基金
美国国家卫生研究院; 英国医学研究理事会; 英国惠康基金;
关键词
CONVERTING ENZYME-INHIBITOR; LIPID-LOWERING TREATMENT; CALCIUM-CHANNEL BLOCKER; CARDIOVASCULAR OUTCOMES; GENETIC ANCESTRY; AFRICAN-AMERICAN; RISK; DISCRIMINATION; PREDICTION; BLACKS;
D O I
10.1016/j.molmed.2024.04.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Population differences in cardiometabolic disease remain unexplained. Misleading assumptions over genetic explanations are partly due to terminology used to distinguish populations, specifically ancestry, race, and ethnicity. These terms differentially implicate environmental and biological causal pathways, which should inform their use. Genetic variation alone accounts for a limited fraction of population differences in cardiometabolic disease. Research effort should focus on societally driven, lifelong environmental determinants of population differences in disease. Rather than pursuing population stratifiers to personalize medicine, we advocate removing socioeconomic barriers to receipt of and adherence to healthcare interventions, which will have markedly greater impact on improving cardiometabolic outcomes. This requires multidisciplinary collaboration and public and policymaker engagement to address inequalities driven by society rather than biology per se.
引用
收藏
页码:541 / 551
页数:11
相关论文
共 50 条